Compare WDC & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WDC | ILMN |
|---|---|---|
| Founded | 1970 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | WDC | ILMN |
|---|---|---|
| Price | $174.31 | $134.79 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 15 |
| Target Price | ★ $149.17 | $114.93 |
| AVG Volume (30 Days) | ★ 7.4M | 1.6M |
| Earning Date | 01-28-2026 | 10-30-2025 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 578.01 | N/A |
| EPS | ★ 6.90 | 4.46 |
| Revenue | ★ $10,126,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | $24.25 | N/A |
| Revenue Next Year | $12.58 | $2.08 |
| P/E Ratio | ★ $25.56 | $30.24 |
| Revenue Growth | ★ 75.22 | N/A |
| 52 Week Low | $28.83 | $68.70 |
| 52 Week High | $188.77 | $153.06 |
| Indicator | WDC | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 67.48 |
| Support Level | $170.02 | $132.70 |
| Resistance Level | $188.77 | $137.09 |
| Average True Range (ATR) | 9.00 | 3.23 |
| MACD | 0.49 | -0.11 |
| Stochastic Oscillator | 64.62 | 77.96 |
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.